ID   B1 [Human hepatocellular carcinoma]
AC   CVCL_A1AS
DR   cancercelllines; CVCL_A1AS
DR   Wikidata; Q102113582
RX   PubMed=31063779;
WW   https://lccl.zucmanlab.com/hcc/cellLines/B1
CC   From: Grasl-Kraupp B.; Medical University of Vienna; Vienna; Austria.
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro152Leu (c.455C>T); ClinVar=VCV000142766; Zygosity=Unspecified (PubMed=31063779).
CC   Omics: Deep exome analysis.
CC   Omics: miRNA expression profiling.
CC   Omics: Protein expression by reverse-phase protein arrays.
DI   NCIt; C3099; Hepatocellular carcinoma
DI   ORDO; Orphanet_88673; Hepatocellular carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 29-10-20; Last updated: 05-10-23; Version: 5
//
RX   PubMed=31063779; DOI=10.1053/j.gastro.2019.05.001;
RA   Caruso S., Calatayud A.-L., Pilet J., La Bella T., Rekik S.,
RA   Imbeaud S., Letouze E., Meunier L., Bayard Q., Rohr-Udilova N.,
RA   Peneau C., Grasl-Kraupp B., de Koning L., Ouine B., Bioulac-Sage P.,
RA   Couchy G., Calderaro J., Nault J.-C., Zucman-Rossi J., Rebouissou S.;
RT   "Analysis of liver cancer cell lines identifies agents with likely
RT   efficacy against hepatocellular carcinoma and markers of response.";
RL   Gastroenterology 157:760-776(2019).
//